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PreviewsNext, they performed microarray profiling
of the co-cultured osteoblasts and found
IL6, a proproliferative cytokine involved in
bone metastasis (Ara et al., 2009), among
the upregulated genes. Using a combina-
tion of strategies, the authors nicely
demonstrate that IL6 is a downstream
target of the Jagged1-Notch-Rbpj-Hey1
cascade, and is released fromosteoblasts
to promote tumor proliferation.
Notch signaling is a central pathway for
regulating cell-cell interaction during
embryonic development and is also
involved in the pathogenesis of skeletal
diseases (Tao et al., 2010). Hence, it is
not unexpected that pharmacological
inhibitors that block Notch pathway
signaling will have a beneficial effect in
both co-cultured Jagged1-expressing
tumor cells and bone cells, as well as in
the mouse model. However, a remaining
clinically relevant question is whether
these inhibitors can inhibit the outgrowth
of bone metastasis in patients. Another
important area that is critical for clinical
translation would be the effect of Notchinhibition in other components of the skel-
etal system (Engin et. al., 2008), as well as
elsewhere in the body.
In summary, the work presented by
Sethi et al. (2011) identified a novel ‘‘seed
and soil’’ crosstalk mediated by the
TGFb-Jagged1-Notch-IL6 signaling
network that promotes the outgrowth of
bone metastasis. The knowledge gained
in this study contributes to our under-
standing of the pathogenesis of bone
metastases and aids in finding therapy
against it. In addition, it opens doors for
many remaining unanswered questions.
Does Jagged1 activate Notch signaling
in other bone marrow-residing cells?
How does Notch pathway interplay with
other factors involved in bonemetastasis?
Will the use of Notch inhibitors together
with inhibitors of IL6 or/and TGFb be
synergistic in halting bone metastasis?REFERENCES
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JAK2 gain-of-function mutations have been shown to cause myeloproliferative neoplasms. In this issue of
Cancer Cell, Liu et al. (2011) demonstrate that these JAK2 mutants, but not wild-type JAK2, directly phos-
phorylate PRMT5 and inhibit its arginine methyltransferase activity, establishing a link between mutant
JAK2 and histone arginine methylation.Janus kinase 2 (JAK2) is a ubiquitously ex-
pressed intracellular tyrosine kinase that
associates with the cytoplasmic domains
of hematopoietic cytokine receptors and
becomes activated upon these receptors
binding to their cognate ligands. Acti-
vatingmutations in JAK2 have been found
in the majority of patients with myelo-
proliferative neoplasms (MPN), which
represent clonal hematopoietic stem
cell diseases characterized by increasedproliferation of the erythroid, megakar-
yocytic, or myeloid lineages. The vast
majority of patients with MPN (about
80%) carry mutations in JAK2 codon
617 that exchanges a valinewith a phenyl-
alanine (JAK2-V617F) (Skoda, 2007).
This mutated JAK2-V617F is an activated
tyrosine kinase that renders hemato-
poietic cells hypersensitive for signals
from upstream cytokine receptors (Epo,
Tpo, and G-CSF) and phosphorylates(STAT3 and STAT5), as well as other
downstream signaling proteins. In
a minority of patients (less than 3% of
MPNs), JAK2 mutations have been found
in codon 539 (e.g., JAK2-K539L) or in
neighboring codons, leading to a variant
of MPN with selectively increased
numbers of erythroid cells. The mutant
JAK2 proteins were shown to activate
proliferation, inhibit apoptosis, and inter-
fere with genome stability. However, allFebruary 15, 2011 ª2011 Elsevier Inc. 161
Figure 1. Oncogenic JAK2 (V617F, K539L) Phosphorylates PRMT5 and Disrupts the
Methylosome
Cancer Cell
Previewsof these effects were also observed when
the wild-type JAK2 was stimulated by
cytokine receptor activation. The failure
of SOCS3 to inhibit JAK2-V617F was
so far the only hint that JAK2-V617F is
not just a constitutively active form of
wild-type JAK2 (Hookham et al., 2007).
The work by Liu et al. (2011) describes
phosphorylation of the protein arginine
methyltransferase 5 (PRMT5) as a novel
activity that is unique to the mutant
JAK2-V617F and JAK2-K539L proteins.
Protein arginine methylation has
emerged as an important mechanism
to regulate protein-protein or protein-
nucleic acid interactions. Today, nine
human PRMTs are known that are classi-
fied into two major categories (class I
and II), based on their substrate and
reaction specificity (Krause et al., 2007).
Class II PRMTs include PRMT5, PRMT7,
and PRMT9, which catalyze the symmet-
rical dimethylation of arginine residues.
PRMT5 activity was previously shown
to be involved in epigenetic modulation
of transcription through methylation of
histones H2A, H3, and H4.
In yeast two-hybrid screenings, PRMT5
was previously identified as a JAK2 inter-
acting protein. Liu et al. (2011) now found
that mutant JAK2 (V617F, K539L) binds
PRMT5 stronger than wild-type JAK2
and phosphorylates PRMT5 in vitro and
in vivo, characterizing PRMT5 as a novel
bona fide substrate of mutated JAK2162 Cancer Cell 19, February 15, 2011 ª2011(Figure 1). Phosphorylation by mutant
JAK2 of PRMT5 reduced its methyltrans-
ferase activity toward recombinant
histones H4 and H2A. Liu et al. (2011)
were also able to narrow down the resi-
dues in PRMT5 that are targeted by
mutant JAK2 to Y297, Y304, and Y307.
The N terminus of JAK2 upstream of the
activating mutations interacts with
PRMT5. Interestingly, phosphorylation of
these PRMT5 residues seemed to disrupt
the association of PRMT5 with MEP50,
a cofactor for the enzymatic activity of the
methylosome. shRNA-mediated knock-
down of PRMT5 in human CD34+ cord
blood cells increased colony formation
in methylcellulose and erythroid differ-
entiation in liquid cultures. In contrast,
overexpression of the wild-type PRMT5
(but not an enzymatically inactive mutant
of PRMT5) decreased hematopoietic
colony formation. Although gene expres-
sion profiling provided a list of potential
downstream effectors, the molecular
mechanisms remain to be elucidated.
Finally, increased phosphorylation of
PRMT5 was detected in all ten MPN
patients with mutant JAK2 that were
examined and interestingly also in one
MPN patient with wild-type JAK2.
Liu et al. (2011) provide a novel link
between oncogenic JAK2 activity and
epigenetic gene regulation. Previous
work implicating JAK2 in epigenetic
events showed that activated JAK2Elsevier Inc.phosphorylates histone H3 at tyrosine
41 and thereby reduces the binding
of the heterochromatin protein HP1a
(Dawson et al., 2009). Exclusion of the
repressor HP1a from chromatin results
in the activation of genes that are not
directly targets of STAT3 or STAT5. The
amplification of a region of chromosome
9p24 in malignant lymphomas harbors,
in addition to JAK2, another gene,
JMJD2C, which demethylates histone
H3 and thereby inhibits HP1a binding
(Rui et al., 2010).
The work of Liu et al. (2011) raises
many interesting questions and possi-
bilities. First, previous studies have
described a connection of the JAK/STAT
signaling pathway with another PRMT
family member, PRMT1. Initially, STAT1
was found to be methylated on arginine
by PRMT1 to be protected from the
inhibitory action by the PIAS1 protein
(Mowen et al., 2001). Very recently,
PRMT1 has been shown to directly
methylate arginine 303 of PIAS1 and
thereby increase the inhibitory activity of
PIAS1 on STAT1-dependent transcrip-
tion (Weber et al., 2009). It remains to
be determined whether in analogy to
PRMT1, PRMT5 might also methylate
PIAS3 and interfere with STAT3-depen-
dent transcription. Interestingly PRMT5
was recently found to physically interact
with STAT3 and proposed to be actively
involved in STAT3-mediated transcrip-
tional repression (Tee et al., 2010).
Second, it will be important to address
whether disrupting PRMT5 alone (or
one of its cofactors) is sufficient to induce
MPN. A conditional knockout of PRMT5 in
the hematopoietic system should provide
the answer. Somatic mutations in PRMT5
have so far not been described in MPN.
Are the effects of decreased PRMT5
activity limited to decreased histone
methylation or are other substrates, such
as p53, involved?
Third, very recent work implicates
increased PRMT5 activity in the tumori-
genesis of mouse lymphoma and human
esophageal carcinoma (Aggarwal et al.,
2010). Here, MEP50 is phosphorylated
by cyclin D1/CDK4 and leads to increased
activity of PRMT5. This suggests that
inhibitors of arginine methyltransferases
could have therapeutic potential. In
contrast, the results of Liu et al. (2011)
imply that blocking PRMT5 would favor
myeloproliferation. Currently, these
Cancer Cell
Previewsapparent opposing effects of PRMT5
activity on tumorigenesis need further
investigation.
Fourth, the observation of increased
phosphorylation of PRMT5 in CD34+ cells
from one MPN patient without activating
JAK2 mutation suggests that other tyro-
sine kinases could phosphorylate
PRMT5. Will impaired PRMT5 also be
the consequence of uncontrolled activity
of tyrosine kinases, such as mutated
ABL, PDGFR, or FLT3, frequently found
in chronic and acute malignant
myeloproliferations?
Finally, since phosphorylation and inhi-
bition of PRMT5 activity are properties
specific for themutated JAK2 proteins, in-
hibiting the interaction between mutant
JAK2 and PRMT5 could potentially inter-fere with MPN pathogenesis without
affecting the wild-type JAK2.REFERENCES
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Bredel et al. (2010) recently identified a subset of glioblastomas that harbormonoallelic loss ofNFKBIA, which
negatively affects patient prognosis. This finding raises newquestions as to the role of IkBa andNF-kB in glio-
blastoma, the relationship between EGFR and NF-kB signaling, and potential therapeutic targets.When we think of mutations that promote
cancer, those used for textbook and
review examples, the NF-kB pathway
does not get a lot of attention. Yet
NF-kB is clearly established as an impor-
tant mediator of oncogenesis (Karin,
2006), and mutations in the immediate
regulatory pathways leading to NF-kB
activation have been characterized
(Courtois andGilmore, 2006). Importantly,
well-established mutations that lead to
cancer, such as activating mutations in
Ras, function oncogenically through
NF-kB activation (Basse`res et al., 2010;
Mayo et al., 1997; Meylan et al., 2009).
New work from Bredel et al. (2010)
demonstrates a fascinating monoallelicdeletion of NFKBIA, in patient-derived
glioblastoma multiforme (GBM). This
gene encodes IkBa, a critical negative
regulator of canonical NF-kB activation.
The work suggests an interesting link
between EGFR-induced signaling in
GBM and the loss of IkBa.
NF-kB is a transcription factor com-
prised of homo- and heterodimers of
five subunits: p65/RelA, RelB, c-Rel,
p105/p50, and p100/p52. Under basal
conditions, IkB molecules (IkBa, b,
and 3 isoforms) sequester p65- and
c-Rel-containing dimers in the cytoplasm.
Full-length p100 and p105 contain similar
motifs to IkB and must be processed to
yield active p50 and p52 subunits. Uponactivation by cytokines or other stimuli,
the IKK complex phosphorylates IkB,
leading to its proteasomal degradation,
which leaves NF-kB free to accumulate in
the nucleus to control target gene expres-
sion. Genes regulated by NF-kB promote
cell proliferation and survival, underlying
the importance of this transcription factor
both in normal cell responses and in onco-
genesis (Karin, 2006).
Due to the integral involvement of
NF-kB in promoting proliferation and the
survival of cells of the hematopoietic
system, it is not surprising that mutations
in this pathway are observed in hemato-
logic malignancies. c-Rel is often ampli-
fied in B cell malignancies and Hodgkin’sFebruary 15, 2011 ª2011 Elsevier Inc. 163
